[REVISION HISTORY]

PMOS Renaming – Heart, Fertility & Mental Health

Updated 7 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-05 19:54 UTC → 2026-09-14 02:15 UTC · added ~~removed~~

Following the May 2026 international consensus renaming polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS), new research and clinical developments have emerged regarding its management and risks. In Australia, the renaming has been officially adopted to better reflect the disorder’s endocrine and metabolic features and to reduce misdiagnosis associated with ovarian cysts. Advocates at the Monash Centre for Health Research and Implementation, including Professor Helena Teede and Dr. Rebecca Taylor, emphasize that the new terminology clarifies the diverse manifestations of the condition to improve care for women planning families. Medical experts note that the previous terminology may have delayed diagnoses by focusing too narrowly on ovarian cysts rather than the condition as a multisystem disorder. Dr. Alena Pichler of the Wunschbaby Institut Baden notes that the old term was misleading because many patients possess numerous small, normal follicles rather than actual cysts. The term ‘polyendocrine’ acknowledges the involvement of multiple hormone systems, while ‘metabolic’ highlights the central role of insulin resistance. PMOS is recognized as a complex endocrine and metabolic condition ~~driven largely by insulin resistance,~~ affecting approximately one in eight women. It can impact blood sugar regulation, mood, energy levels, and long-term heart health, with increased risks for type 2 diabetes, high blood pressure, and fatty liver disease. ~~While frequently associated with infertility, experts emphasize that many women can restore ovulation through medical treatment.~~ Clinical studies continue to highlight significant cardiovascular ~~risks. A~~ risks, with a University of Pennsylvania analysis ~~reports~~ reporting that women with PMOS are four times more likely to develop cardiovascular disease. Regarding treatment, GLP-1 obesity medications are showing promise for improving insulin resistance and hormone balance. A global coalition of health leaders is now calling for urgent research into PMOS subtypes to address a projected surge in prevalence among adolescents and young women by 2036.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.